Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Neoplasm|Cervical Squamous Cell Carcinoma|Endometrial Carcinoma|Malignant Uterine Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Malignant Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Solid Neoplasm|Stage III Bladder Cancer|Stage III Prostate Cancer|Stage III Renal Cell Cancer|Stage IIIA Breast Cancer|Stage IIIA Cervical Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Breast Cancer|Stage IIIB Cervical Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Breast Cancer|Stage IIIC Ovarian Cancer|Stage IV Breast Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IVA Bladder Cancer|Stage IVA Cervical Cancer|Stage IVB Bladder Cancer|Stage IVB Cervical Cancer
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Nanoparticle Albumin-Bound Rapamycin|OTHER: Quality-of-Life Assessment
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)